Adverum Biotechnologies granted ILAP designation for Ixo-vec in Wet AMD

Adverum Biotechnologies announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency as granted Ixo-vec, an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway. The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence and the National Health Service England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom.